Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
LITESPARK-013
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
- NCT04489771 ↗
- Completed
- Merck Sharp & Dohme LLC
- Deep
We haven't built an HCP commentary report on LITESPARK-013 (belzutifan in advanced clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LITESPARK-013 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 24 | |
| Podcasts | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Belzutifan
- Arms
- Belzutifan 200 mg · Experimental
- Belzutifan 120 mg · Experimental
- Enrollment
- 154
- Primary outcomes
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Sep 13, 2020
- Primary completion
- Feb 10, 2023
- Results posted
- Yes
- Registry record
- NCT04489771 · updated Sep 24, 2026
Publications
linked from the registry- Agarwal N, Brugarolas J, Ghatalia P, George S, Haanen JB, Gurney H, Ravilla R, Van der Veldt A, Beuselinck B, Pokataev I, Suelmann BBM, Tuthill MH, Vaena D, Zagouri F, Wu J, Perini RF, Liu Y, Merchan J, Atkins MB. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Ann Oncol. 2024 Dec;35(12):1148-1156. doi: 10.1016/j.annonc.2024.08.2338. Epub 2024 Sep 2. PubMed 39233312